MA42623A - Inhibiteurs de la tyrosine kinase de bruton - Google Patents
Inhibiteurs de la tyrosine kinase de brutonInfo
- Publication number
- MA42623A MA42623A MA042623A MA42623A MA42623A MA 42623 A MA42623 A MA 42623A MA 042623 A MA042623 A MA 042623A MA 42623 A MA42623 A MA 42623A MA 42623 A MA42623 A MA 42623A
- Authority
- MA
- Morocco
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- bruton tyrosine
- bruton
- inhibitors
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169941P | 2015-06-02 | 2015-06-02 | |
| US201562169935P | 2015-06-02 | 2015-06-02 | |
| US201562169945P | 2015-06-02 | 2015-06-02 | |
| US201562249338P | 2015-11-01 | 2015-11-01 | |
| US201562249336P | 2015-11-01 | 2015-11-01 | |
| US201562249340P | 2015-11-01 | 2015-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42623A true MA42623A (fr) | 2018-06-20 |
Family
ID=57441893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042623A MA42623A (fr) | 2015-06-02 | 2016-06-02 | Inhibiteurs de la tyrosine kinase de bruton |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180305348A1 (fr) |
| EP (1) | EP3310776A4 (fr) |
| JP (1) | JP2018522823A (fr) |
| KR (1) | KR20180021740A (fr) |
| CN (1) | CN107709315A (fr) |
| AU (2) | AU2016270907B2 (fr) |
| BR (1) | BR112017025986A2 (fr) |
| CA (1) | CA2987054A1 (fr) |
| IL (1) | IL255831A (fr) |
| MA (1) | MA42623A (fr) |
| MX (1) | MX2017015574A (fr) |
| RU (1) | RU2017145650A (fr) |
| SG (1) | SG10201911523YA (fr) |
| WO (1) | WO2016196776A2 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY203083A (en) * | 2016-12-21 | 2024-06-07 | Acerta Pharma Bv | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
| KR101956815B1 (ko) * | 2017-02-14 | 2019-03-12 | 한국화학연구원 | 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| KR102797697B1 (ko) | 2018-05-25 | 2025-04-22 | 에이2에이 파마수티칼스, 잉크. | 신종 항암제 후보로서, 매우 강력한 tacc3 억제제 |
| CN113412259B (zh) | 2018-10-15 | 2024-07-16 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
| HRP20250048T1 (hr) | 2018-10-22 | 2025-03-28 | Alumis Inc. | Inhibitori tyk2 i njihova uporaba |
| WO2020167518A1 (fr) * | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome |
| EP3942045A1 (fr) | 2019-03-21 | 2022-01-26 | Onxeo | Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer |
| AU2020272937B2 (en) | 2019-04-09 | 2024-09-26 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| JP7587528B2 (ja) | 2019-05-17 | 2024-11-20 | ニューリックス セラピューティクス，インコーポレイテッド | Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用 |
| CA3144450A1 (fr) | 2019-06-26 | 2020-12-30 | Nurix Therapeutics, Inc. | Composes benzyl-triazoles substitues pour l'inhibition de cbl-b et autres utilisations de ces composes |
| US12121540B2 (en) | 2019-09-24 | 2024-10-22 | Nurix Therapeutics, Inc. | CBL inhibitors and compositions for use in adoptive cell therapy |
| EP4054579A1 (fr) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase |
| MX2022006672A (es) | 2019-12-04 | 2022-08-08 | Nurix Therapeutics Inc | Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina. |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| BR112022022220A2 (pt) * | 2020-06-01 | 2022-12-13 | Wigen Biomedicine Tech Shanghai Co Ltd | Composto, composição farmacêutica, uso do composto, e método para tratar, regular e/ou prevenir uma doença relacionada a uma proteína mutante de egfr |
| WO2022071772A1 (fr) * | 2020-09-29 | 2022-04-07 | (주)메디톡스 | Inhibiteur de protéine kinase et son utilisation |
| MX2023011883A (es) | 2021-04-08 | 2023-11-09 | Nurix Therapeutics Inc | Terapias combinadas con compuestos inhibidores de cbl-b. |
| WO2022221194A1 (fr) * | 2021-04-12 | 2022-10-20 | A2A Pharmaceuticals, Inc. | Compositions et méthodes de traitement du cancer |
| CA3223769A1 (fr) * | 2021-07-01 | 2023-01-05 | Xinglu ZHOU | Tyrosine kinase de bruton et agent de degradation mutant, composition et utilisation associees |
| WO2023076303A1 (fr) | 2021-10-26 | 2023-05-04 | Nurix Therapeutics, Inc. | Composés de pipéridinylpyrazine-carboxamide pour le traitement et la prévention du cancer et pour la dégradation de btk |
| WO2023088477A1 (fr) * | 2021-11-22 | 2023-05-25 | 杭州和正医药有限公司 | Composé multifonctionnel capable de dégrader la kinase btk, composition et utilisation |
| EP4499625A4 (fr) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | Compositions et méthodes de traitement du cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| AU5107900A (en) * | 1999-06-09 | 2000-12-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| EP2763976B1 (fr) * | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide |
| SG11201402570QA (en) * | 2011-11-23 | 2014-06-27 | Portola Pharm Inc | Pyrazine kinase inhibitors |
| KR20140108594A (ko) * | 2012-01-10 | 2014-09-11 | 에프. 호프만-라 로슈 아게 | 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도 |
| WO2013108754A1 (fr) * | 2012-01-17 | 2013-07-25 | アステラス製薬株式会社 | Composé pyrazine carboxamide |
| US20140113931A1 (en) * | 2012-06-22 | 2014-04-24 | Portola Pharmaceuticals, Inc. | Substituted picolinamide kinase inhibitors |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| WO2014135473A1 (fr) * | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | Inhibiteurs de tyrosine kinase de bruton |
| WO2014153280A1 (fr) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant du 2-pyridyl carboxamide |
| CN104262328B (zh) * | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| EP3077388A1 (fr) * | 2013-12-05 | 2016-10-12 | Pharmacyclics, LLC | Inhibiteurs de la tyrosine kinase de bruton |
-
2016
- 2016-06-02 MA MA042623A patent/MA42623A/fr unknown
- 2016-06-02 RU RU2017145650A patent/RU2017145650A/ru not_active Application Discontinuation
- 2016-06-02 AU AU2016270907A patent/AU2016270907B2/en not_active Ceased
- 2016-06-02 BR BR112017025986A patent/BR112017025986A2/pt not_active IP Right Cessation
- 2016-06-02 CA CA2987054A patent/CA2987054A1/fr not_active Abandoned
- 2016-06-02 SG SG10201911523YA patent/SG10201911523YA/en unknown
- 2016-06-02 JP JP2017560655A patent/JP2018522823A/ja active Pending
- 2016-06-02 EP EP16804424.6A patent/EP3310776A4/fr not_active Withdrawn
- 2016-06-02 CN CN201680035113.2A patent/CN107709315A/zh active Pending
- 2016-06-02 KR KR1020177037849A patent/KR20180021740A/ko not_active Withdrawn
- 2016-06-02 US US15/579,142 patent/US20180305348A1/en not_active Abandoned
- 2016-06-02 WO PCT/US2016/035489 patent/WO2016196776A2/fr not_active Ceased
- 2016-06-02 MX MX2017015574A patent/MX2017015574A/es unknown
-
2017
- 2017-11-21 IL IL255831A patent/IL255831A/en unknown
-
2019
- 2019-07-17 US US16/514,544 patent/US20210070748A1/en not_active Abandoned
-
2020
- 2020-12-11 AU AU2020286332A patent/AU2020286332A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180021740A (ko) | 2018-03-05 |
| WO2016196776A3 (fr) | 2017-01-05 |
| CN107709315A (zh) | 2018-02-16 |
| RU2017145650A3 (fr) | 2019-11-22 |
| EP3310776A4 (fr) | 2019-01-16 |
| SG10201911523YA (en) | 2020-02-27 |
| WO2016196776A2 (fr) | 2016-12-08 |
| US20210070748A1 (en) | 2021-03-11 |
| BR112017025986A2 (pt) | 2018-08-14 |
| MX2017015574A (es) | 2018-08-09 |
| JP2018522823A (ja) | 2018-08-16 |
| IL255831A (en) | 2018-01-31 |
| AU2016270907B2 (en) | 2020-09-17 |
| EP3310776A2 (fr) | 2018-04-25 |
| RU2017145650A (ru) | 2019-07-15 |
| AU2016270907A1 (en) | 2017-12-07 |
| CA2987054A1 (fr) | 2016-12-08 |
| AU2020286332A1 (en) | 2021-01-21 |
| US20180305348A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279258B (en) | tyrosine kinase inhibitors | |
| EP3414234A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
| BR112017025986A2 (pt) | inibidores de tirosina quinase de bruton. | |
| MA43162A (fr) | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton | |
| EP3541932A4 (fr) | Inhibiteurs de crispr-cas9 | |
| EP3347018A4 (fr) | Inhibiteurs de kinases cycline-dépendantes | |
| LT3580220T (lt) | Aminotriazolopiridinai, kaip kinazės inhibitoriai | |
| EP3405192A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3283077A4 (fr) | Inhibiteurs de bromodomaine | |
| EP3247692A4 (fr) | Inhibiteurs de trka kinase | |
| CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
| HUE050842T2 (hu) | Janus-kináz inhibitor | |
| BR112017002232A2 (pt) | combinações de inibidor de tirosina quinase de bruton e usos das mesmas | |
| MA44474A (fr) | Nouveaux inhibiteurs de la ferroportine | |
| EP3442972A4 (fr) | Inhibiteurs de bromodomaine | |
| DK3290418T3 (da) | Janus Kinase (JAK)-hæmmere | |
| EP3313828A4 (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| BR112017020743A2 (pt) | cocristais de um inibidor da tirosina cinase de bruton. | |
| LT3728207T (lt) | Chinazolinonai kaip parp14 inhibitoriai | |
| BR112017015206A2 (pt) | síntese de um inibidor de tirosina quinase de bruton | |
| LT3704118T (lt) | Aminoimidazopiridazinai, kaip kinazės inhibitoriai | |
| EP3349754A4 (fr) | Inhibiteurs de pcna | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| EP3555092A4 (fr) | Inhibiteurs de protéine kinase |